Amarantus BioScience “2014: Initiation of Eltoprazine Phase 2b and LymPro Commercialization”

Publishing & Media

Share Tweet

Amarantus BioScience “2014: Initiation of Eltoprazine Phase 2b and LymPro Commercialization”

Amarantus BioScience, Inc. (OTCQB: AMBS) published a new blog post on The Chairman’s Blog, written by the company’s CEO, Gerald Commissiong. is an exclusive online media publication that provides key executive officers and key opinion leaders a unique platform to share insights about company and industry trends. 

Amarantus CEO, Gerald Commissiong, reflects on the effect the recently announced in-licensing of Eltoprazine for Parkinson’s disease will have on the company’s value. With increased focus on the company’s pipeline, Mr. Commissiong sees it as “an opportunity for the public to review [Amarantus’] pipeline and become familiar with [Amarantus’] LymPro diagnostic blood test for Alzheimer’s disease (AD).”  Read his full blog post on (  

About Amarantus

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test (“LymPro Test®”) for Alzheimer’s disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease (“NuroPro”) and the discovery of neurotrophic factors (“PhenoGuard”). For further information please visit, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.  

About is an exclusive, online media publication where publically and privatively held firms alike share insights about their companies and industries. enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. In addition to management`s insightful blog posts, staff and aggregate partners contribute articles on finance, technology, health, and energy while providing updated market trends, news, and information.